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Abstract
Indonesia is one of the countries with the highest multidrug-resistant tuberculosis cases in the world. Rapid 
molecular test using the Xpert MTB/RIF assay is one of the detection methods for MDR-TB. Early detection of MDR-
TB is crucial for early initiation of treatment. However, Xpert MTB/RIF assay only detects the rpoB gene mutations 
associated with Rifampicin resistance. Recently, WHO recommends the use of Pyrosequencing, a DNA sequencing 
method that can detect not only the rpoB gene but also katG and/or inhA gene mutations associated with Isoniazid 
resistance. The aims of this study were to compare the interpretation between the two methods  and to determine 
the differences in codon mutation position detection of the rpoB gene and mutation detection of the katG and/or 
inhA gene. This was a cross-sectional comparative observational study on patients ≥18 years old interpreted as 
RR-TB patients based on Xpert MTB/RIF assay results who had not received MDR-TB drugs at Dr. Hasan Sadikin 
General Hospital Bandung, Indonesia. Results showed there were 40 Rifampicin-resistant TB subjects interpreted 
by Xpert MTB/RIF assay while Pyrosequencing interpreted 30 MDR-TB, 9 RR-TB and one Isoniazid-resistant TB 
subjects in January–February 2020. The detection of rpoB gene codon mutation position between Xpert MTB/RIF 
assay and Pyrosequencing methods was not significantly different (p=0.389). Pyrosequencing had detected 27 
katG gene mutations, 3 inhA gene mutations, one katG and inhA gene mutation. To conclude, Pyrosequencing can 
be used for accurate detection of Rifampicin and Isoniazid resistance in MDR-TB.
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Perbandingan Hasil Interpretasi antara Pyrosequencing dengan Xpert MTB/
RIF Assay pada Multidrug-Resistant Tuberculosis
Abstrak
Indonesia merupakan salah satu negara dengan kasus multidrug-resistant tuberculosis terbanyak. Penegakan 
diagnosis MDR-TB saat ini menggunakan tes cepat molekular Xpert MTB/RIF assay sehingga pasien segera 
mendapatkan pengobatan. Namun, Xpert MTB/RIF assay hanya mendeteksi mutasi gen rpoB penyandi resistansi 
Rifampisin. World Health Organization merekomendasikan Pyrosequencing, metode sequencing nukleotida yang 
dapat mendeteksi mutasi gen rpoB, gen katG dan/atau inhA penyandi resistansi Isoniazid. Tujuan penelitian 
ini adalah menentukan apakah kedua alat ini memberikan hasil interpretasi yang sama, apakah ada perbedaan 
deteksi posisi mutasi kodon gen rpoB dan apakah ditemukan mutasi gen katG dan/atau inhA. Penelitian ini 
merupakan studi observasional komparatif dengan rancangan cross-sectional. Subjek penelitian adalah pasien 
usia ≥18 tahun yang diinterpretasi RR-TB berdasarkan Xpert MTB/RIF assay di RSUP Dr. Hasan Sadikin Bandung 
dan belum mendapat pengobatan. Xpert MTB/RIF assay menginterpretasi 40 subjek Rifampicin-resistant TB 
sedangkan Pyrosequencing menginterpretasi 30 subjek MDR-TB, 9 subjek RR-TB, dan satu subjek Isoniazid-
resistant TB pada bulan Januari–Februari 2020. Deteksi posisi mutasi kodon gen rpoB antara Xpert MTB/RIF 
assay dan Pyrosequencing tidak berbeda bermakna (p=0,389). Pyrosequencing mendeteksi 27 mutasi gen katG, 
3 mutasi gen inhA, satu mutasi gen katG dan inhA. Kesimpulan, Pyrosequencing dapat digunakan untuk deteksi 
resistansi Rifampisin dan Isoniazid pada MDR-TB secara lebih akurat.
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Introduction
Indonesia has the third-highest number of 
tuberculosis (TB) cases worldwide and is one 
of the countries with the highest multidrug-
resistant tuberculosis (MDR-TB) cases.1 
Multidrug-resistant tuberculosis is a form of TB 
infection caused by Mycobacterium tuberculosis 
(MTB) resistant to at least two of the most 
powerful first-line anti-TB drug treatments: 
Rifampicin and Isoniazid.1,2 Xpert MTB/RIF 
assay is recommended by the World Health 
Organization (WHO) since 2010 as an initial test 
to diagnose MDR-TB.3,4 Xpert MTB/RIF assay is 
a semi-quantitative nested real-time polymerase 
chain reaction (PCR) test that can detect 
deoxyribonucleic acid (DNA) of MTB rapidly. 
This test is also easy to perform and can detect 
rpoB gene mutations that are associated with 
Rifampicin resistance using 5 probes (A, B, C, D, 
and E).5,6 
Rifampicin resistance is determined by 
detecting maximal ∆ threshold cycle (CT) >4 cycles 
or 1-3 probes that are not complementary to 81 
base pairs (bp) rpoB core region.6 However, the 
Xpert MTB/RIF assay only detects the rpoB gene 
mutations as Rifampicin resistance is a surrogate 
marker of MDR-TB.2,5,7 Rifampicin-resistant 
TB (RR-TB) interpreted by the Xpert MTB/RIF 
assay diagnosed as MDR-TB was less accurate 
because the Xpert MTB/RIF assay cannot detect 
katG, inhA, and/or ahpC gene mutations that are 
associated with Isoniazid resistance.8,9
Pyrosequencing is a DNA analysis based 
on nucleotide sequencing by inorganic 
pyrophosphate (PPi) synthesis to know nucleotide 
mutations directly and specifically.10,11 Recently, 
WHO recommends MDR-TB early detection 
using Pyrosequencing.12 Pyrosequencing using 
Pyromark Q48 Reagents Kit can detect the 81bp 
rpoB gene as Rifampicin resistance determining 
region (RRDR) mutations from 507 until 533 
codons and katG and/or inhA gene mutations 
that are associated with Rifampicin and Isoniazid 
resistance.13 
Therefore, Pyrosequencing can diagnose 
MDR-TB more accurately.10,11,13 This study aimed 
to determine whether these two methods have 
the same interpretation and to determine the 
differences in codon mutation position detection 
of the rpoB gene as well as mutation detection 
of the katG and/or inhA gene based on the 
Pyrosequencing results.
Methods
A comparative observational study with a cross-
sectional design was used in this study. Subjects 
were patients ≥18 years old interpreted as RR-TB 
based on the Xpert MTB/RIF assay results from 
Dr. Hasan Sadikin General Hospital Bandung, 
Indonesia, who had not received MDR-TB drugs 
yet. This study used 40 biological materials 
from sputum stored in the form of DNA isolates 
in -80⁰C freezer under daily temperature 
monitoring from a study on the association 
between minimum inhibitory concentration 
and gene mutation related to drug resistance in 
patients with multi/extensively drug-resistant 
tuberculosis in Indonesia in 2015. There was 
no electricity problem during the storage 
period. The exclusion criteria was the volume of 
biological materials <20 µL. Sputum used for the 
Pyrosequencing differed from the Xpert MTB/
RIF assay. 
This study was conducted at the TB 
Biomolecular Laboratorium of the West Java 
Provincial Health Laboratory, Indonesia during 
the period of January-February 2020. The 
real-time PCR Quality Control (QC) used DNA 
template and primer to amplify the IS6110 
gene as MTB positive control. Pyrosequencing 
detected the IS6110 gene and genetic mutations 
within rpoB, inhA, katG, eis, gyrA, and rrs gene. 
Pyrogram and its interpretation were released 
after the Pyrosequencing process.13  This study 
was approved by the Health Research Ethics 
Committee of Universitas Padjadjaran Bandung 
through the issuance of ethical approval no. 
77/UN6.KEP/EC/2020. Data analysis were 
performed using the Statistical Package for the 
Social Sciences (SPSS) software version 24.0 for 
Windows. 
Results
In total, 40 RR-TB subjects based on the 
interpretation using the Xpert MTB/RIF assay 
were recruited. When the samples underwent 
Pyrosequencing, 30 MDR-TB subjects, 9 RR-TB 
subjects, and one Isoniazid-resistant TB subject 
were identified as listed in Table 1.
The proportion of codon mutation position 
detection of the rpoB gene between the Xpert 
MTB/RIF assay and the Pyrosequencing 
methods are presented in Table 2. Mutation in 
529-533 codons was the most prevalent, and 
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Table 1 Rifampicin-Resistant Tuberculosis Interpretation Based on the Xpert    MTB/RIF Assay  
 and Pyrosequencing (n=40)
Variable
Interpretation
Xpert MTB/RIF Assay Pyrosequencing
n (%) (n=40)(%)
RR-TB 40 (100.0) 9 (22.5)
MDR-TB 0 (0.0) 30 (75.0)
Isoniazid-resistant TB 0 (0.0) 1 (2.5)
RR-TB= Rifampicin-resistant tuberculosis; MDR-TB (multidrug-resistant tuberculosis)=resistance to both Rifampicin 
and Isoniazid with or without resistance to other anti-tuberculosis drugs; categorical data served in amount/frequency 
and percentage
Table 2 Proportion of Codon Mutation Position Detection of the rpoB Gene Between the Xpert  
 MTB/RIF assay and the Pyrosequencing Methods
Variable
Method
p ValueXpert MTB/RIF Assay Pyrosequencing
(n=0) (%) (n=40) (%)
Codon mutation position 
detection of the rpoB Gene
0.389
507–511 Codons 0 (0.0) 0 (0.0)
512–518 Codons 8 (20.0) 10 (25.0)
518–523 Codons 0 (0.0) 0 (0.0)
523–529 Codons 11 (27.5) 11 (27.5)
529–533 Codons 21 (52.5) 18 (45.0)
Not Found 0 (0.0) 1 (2.5)
 p-value counted by Wilcoxon test for ordinal data; p<0.05 has a significant difference
Table 3 katG and inhA Gene Mutation 
Detection by Pyrosequencing
Variable (n=40) (%)
Gene mutation detection 
katG gene 27 (67.5)
inhA gene 3 (7.5)
katG & inhA gene 1 (2.5)
No katG & inhA gene mutation 9 (22.5)
categorical data served in amount/frequency and 
percentage
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was found in 21 (52.5%) subjects by the Xpert 
MTB/RIF assay and 18 (45.0%) subjects by the 
Pyrosequencing. Although the proportion of 
codon mutation position detection of the rpoB 
gene between the Xpert MTB/RIF assay and 
the Pyrosequencing method was not the same, 
they were not significantly different (p=0.389). 
Two subjects had additional codon mutation 
positions detected in 512–518 codons by the 
Pyrosequencing. Pyrosequencing detected 27 
katG gene mutations, 3 inhA gene mutations, 
one katG, and inhA gene mutation, and 9 with no 
katG and inhA gene mutations as demonstrated 
in Table 3.
katG gene mutation detection based on the 
Pyrosequencing was found more than inhA gene 
mutation detection, with 27 subjects or 67.5% 
from 40 RR-TB subjects based on the Xpert MTB/
RIF assay.
Discussion
To the best of our knowledge, this was the first 
study to compare the interpretation between the 
Xpert MTB/RIF assay and the Pyrosequencing 
in MDR-TB in Indonesia. There were 40 RR-
TB subjects from the Xpert MTB/RIF assay 
interpretation diagnosed as MDR-TB, based 
on the Pyrosequencing method. There were 
30 MDR-TB subjects, 9 RR-TB subjects, and 
one Isoniazid-resistant TB participated in this 
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study.2,10,11,13 Pyrosequencing interpreted one 
Isoniazid-resistant TB subject from 40 RR-TB 
subjects based on the Xpert MTB/RIF assay. It 
was assumed that the mutation in the rpoB gene 
detected by the Xpert MTB/RIF assay might not 
be covered by Pyrosequencing. 
A thorough internal QC was performed for 
the Xpert MTB/RIF assay. All samples passed 
the Sample Processing Control (SPC) and 
Probe Check Control (PCC).5,14 Mycobacterium 
tuberculosis was detected in all samples through 
minimal 4 from 5 probes produced fluorescence 
at CT  ≤39 cycles for A, B, and C probes and also CT 
≤36 cycles for D and E probes with ∆CT minimum 
<2 cycles.14 Real-time PCR QC had been done to 
all samples using primers that amplified IS6110 
gene as MTB positive control, rpoB1, rpoB2, inhA, 
katG, eis, gyrA, and rrs gene until CT value was 
seen. Pyrosequencing had detected the IS6110 
gene, rpoB1, rpoB2, inhA, katG, eis, gyrA, and rrs 
gene in all samples. All samples also passed the 
control negative test passed.13 This discrepancy 
could relate to the MTB dual-population or 
heteroresistance.15 Heteroresistance might be 
particularly common in regions with a high rate 
of TB, especially drug-resistant TB. About 1,37-
28,8% of patients infected by MTB might have 
Rifampicin heteroresistance in their body.16 
Rifampicin-sensitive and Rifampicin-resistant 
MTB could be detected by phenotypic and/or 
genotypic drug susceptibility testing (DST) of 
MTB from the same sample that contained ≥1% 
Rifampicin-resistant MTB.16,17 
Although the proportion of codon mutation 
position detection of the rpoB gene between the 
Xpert MTB/RIF assay and the Pyrosequencing 
methods was not the same, they were not 
significantly different (p=0.389) either. This 
discrepancy could relate to MTB heteroresistance. 
There was a change in the base sequence of DNA 
that differed from the rpoB gene wild-type. There 
were two Rifampicin-resistant MTB populations 
from one MTB culture isolate with a different 
base sequence of the rpoB gene based on the 
Pyrosequencing.18 Discrepancy could relate with 
different samples used.16 This study used two 
samples from one subject who had not received 
MDR-TB drugs yet for the Xpert MTB/RIF assay 
and the Pyrosequencing tests.
Heteroresistance happened in two subjects 
who had rpoB gene mutations in one codon 
based on the Xpert MTB/RIF assay while 
the Pyrosequencing had detected rpoB gene 
mutations in two codons. There were rpoB gene 
mutations in 516 and 531 codons based on 
the Pyrosequencing, while the Xpert MTB/RIF 
assay had detected rpoB gene mutation in 529-
533 codons (Probe E). There were rpoB gene 
mutations in 516 and 526 codons based on the 
Pyrosequencing, while the Xpert MTB/RIF assay 
had detected rpoB gene mutation in 523–529 
codons (Probe D). A patient might be infected 
with ≥1 MTB strain with different patterns of 
drug resistance.19 
Pyrosequencing had detected 27 katG gene 
mutations or 67.5%, 3 inhA gene mutations or 
7.5%, one katG and inhA gene mutation or 2.5%, 
and 9 with no katG and inhA gene mutations 
or 22.5% from 40 RR-TB subjects based on 
the Xpert MTB/RIF assay. There were 50-95% 
Isoniazid-resistant TB caused by katG gene 
mutations while 20–35% was caused by inhA 
gene mutations.8,20 katG gene mutations detected 
by the Pyrosequencing were found more than 
inhA gene mutations in this study. Nine subjects 
had no katG and inhA gene mutations with rpoB 
gene mutations interpreted as RR-TB based on 
the Pyrosequencing. This study has encountered 
limitation because confirmation test with Whole 
Genome Sequencing (WGS) for the subjects that 
have discrepancy interpretation between the 
Xpert MTB/RIF assay and the Pyrosequencing 
has not been done yet, due to a high cost.
To conclude, the interpretation between the 
Xpert MTB/RIF assay and the Pyrosequencing 
in MDR-TB is different. There are 40 RR-
TB subjects from the Xpert MTB/RIF assay 
interpretation diagnosed as MDR-TB, based on 
the Pyrosequencing method. There are 30 MDR-
TB subjects, 9 RR-TB subjects, and one Isoniazid-
resistant TB. The detection of rpoB gene codon 
mutation position between the Xpert MTB/
RIF assay and the Pyrosequencing methods is 
not significantly different (p=0.389). The Xpert 
MTB/RIF assay diagnoses MDR-TB based on 
Rifampicin resistance even though the definition 
of MDR-TB is resistance to at least two of the 
most potent tuberculosis drugs, Rifampicin and 
Isoniazid while the Pyrosequencing can detect 
MDR-TB based on resistance to Rifampicin and 
Isoniazid. The advantages of Xpert MTB/RIF 
assay are rapid and easy to perform. Therefore, 
the Xpert MTB/RIF assay can be used for MDR-
TB screening, while the Pyrosequencing can 
detect MDR-TB more accurately although it 
needs a longer time.
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